Intarcia Therapeutics, a US-based biopharmaceutical firm whose name is derived from the Latin for insert, has nearly doubled the equity it has raised over the past 15 years with its latest $160m round.
Intarcia said its combined $160m sale of shares and $50m debt placement was “the largest sum to be raised by a private biotechnology company in at least 25 years”.
Venture capital firms New Enterprise Associates (NEA), New Leaf Venture Partners, Venrock, Alta Partners and Foresite Capital, secondaries…
